RHYTHM PHARMACEUTICALS INC (RYTM) Stock Overview
NASDAQ:RYTM - US76243J1051 - Common Stock
RYTM Key Statistics, Chart & Performance
The current stock price of RYTM is 103.15 USD. In the past month the price increased by 16.82%. In the past year, price increased by 118.12%.
RYTM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About RYTM
Company Profile
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The company is headquartered in Boston, Massachusetts and currently employs 283 full-time employees. The company went IPO on 2017-10-05. The firm is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
Company Info
RHYTHM PHARMACEUTICALS INC
222 Berkeley Street, 12th Floor
Boston MASSACHUSETTS 02116 US
CEO: David P. Meeker
Employees: 283
Phone: 18572644280
RHYTHM PHARMACEUTICALS INC / RYTM FAQ
What is the stock price of RHYTHM PHARMACEUTICALS INC today?
The current stock price of RYTM is 103.15 USD. The price decreased by -1.04% in the last trading session.
What is the ticker symbol for RHYTHM PHARMACEUTICALS INC stock?
The exchange symbol of RHYTHM PHARMACEUTICALS INC is RYTM and it is listed on the Nasdaq exchange.
On which exchange is RYTM stock listed?
RYTM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RHYTHM PHARMACEUTICALS INC stock?
20 analysts have analysed RYTM and the average price target is 113.29 USD. This implies a price increase of 9.83% is expected in the next year compared to the current price of 103.15. Check the RHYTHM PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RHYTHM PHARMACEUTICALS INC worth?
RHYTHM PHARMACEUTICALS INC (RYTM) has a market capitalization of 6.85B USD. This makes RYTM a Mid Cap stock.
How many employees does RHYTHM PHARMACEUTICALS INC have?
RHYTHM PHARMACEUTICALS INC (RYTM) currently has 283 employees.
What are the support and resistance levels for RHYTHM PHARMACEUTICALS INC (RYTM) stock?
RHYTHM PHARMACEUTICALS INC (RYTM) has a support level at 73.09 and a resistance level at 103.27. Check the full technical report for a detailed analysis of RYTM support and resistance levels.
Is RHYTHM PHARMACEUTICALS INC (RYTM) expected to grow?
The Revenue of RHYTHM PHARMACEUTICALS INC (RYTM) is expected to grow by 45.4% in the next year. Check the estimates tab for more information on the RYTM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy RHYTHM PHARMACEUTICALS INC (RYTM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RYTM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RYTM, evaluating the profitability, health, valuation and growth aspects
- RHYTHM PHARMACEUTICALS INC (RYTM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RHYTHM PHARMACEUTICALS INC (RYTM) Sales and EPS estimates to see what analysts future expectations are.
- RHYTHM PHARMACEUTICALS INC (RYTM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RHYTHM PHARMACEUTICALS INC (RYTM) Insider and Institutional Ownership to learn about the owners and their transactions.
- RHYTHM PHARMACEUTICALS INC (RYTM) Stock Chart to make your own analysis
- RHYTHM PHARMACEUTICALS INC (RYTM) Latest news and press-releases to stay up to date.
Does RHYTHM PHARMACEUTICALS INC (RYTM) stock pay dividends?
RYTM does not pay a dividend.
When does RHYTHM PHARMACEUTICALS INC (RYTM) report earnings?
RHYTHM PHARMACEUTICALS INC (RYTM) will report earnings on 2025-11-03, before the market open.
What is the Price/Earnings (PE) ratio of RHYTHM PHARMACEUTICALS INC (RYTM)?
RHYTHM PHARMACEUTICALS INC (RYTM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.01).
What is the Short Interest ratio of RHYTHM PHARMACEUTICALS INC (RYTM) stock?
The outstanding short interest for RHYTHM PHARMACEUTICALS INC (RYTM) is 7.3% of its float. Check the ownership tab for more information on the RYTM short interest.
RYTM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RYTM. When comparing the yearly performance of all stocks, RYTM is one of the better performing stocks in the market, outperforming 96.41% of all stocks.
RYTM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RYTM. The financial health of RYTM is average, but there are quite some concerns on its profitability.
RYTM Financial Highlights
Over the last trailing twelve months RYTM reported a non-GAAP Earnings per Share(EPS) of -3.01. The EPS increased by 33.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.55% | ||
| ROE | -141.04% | ||
| Debt/Equity | 0.79 |
RYTM Forecast & Estimates
20 analysts have analysed RYTM and the average price target is 113.29 USD. This implies a price increase of 9.83% is expected in the next year compared to the current price of 103.15.
For the next year, analysts expect an EPS growth of 32.82% and a revenue growth 45.4% for RYTM